-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran
Original Research
(2262) Views (725) Full article downloads
Authors: Naghmeh Mokhber, Carol J Lane, Mohamad R Azarpazhooh, Elham Salari, Reza Fayazi, et al
Published Date May 2008
Volume 2008:4(1) Pages 227 - 234
DOI: http://dx.doi.org/10.2147/NDT.S2316
Naghmeh Mokhber1, Carol J Lane2, Mohamad R Azarpazhooh3, Elham Salari4, Reza Fayazi5, Mohamad T Shakeri6, Allan H Young7
1Assistant Professor of Psychiatry, 3Assistant Professor of Neurology, 4Mashhad Department of Forensic Psychiatry, 5Assistant Professor of Psychiatry, 6Assistant Professor of Statistics, Mashhad University of Medical Science, Mashhad, Iran; 2Department of Psychiatry, University of British Columbia, Vancouver, Canada7
Abstract: The treatment of dysphoric mania is challenging given the need to treat symptoms of both depression and mania simultaneously without provoking any clinical exacerbation. The newer antiepileptic drugs such as gabapentin, lamotrogine, and carbamazepine are often used as adjuncts to either lithium or valproic acid in the treatment of bipolar disorder. We decided to undertake a monotherapy trial because previous evidence suggested mixed states may be more responsive to anticonvulsants than more traditional antimanic agents. 51 patients with a DSM IV diagnosis of dysphoric mania were randomized to three groups comprising gapbapentin, lamotrogine or carbamazepine and followed for 8 weeks. Psychiatric diagnosis was verified by the structural clinical interview for the DSM-IV (SCID). The MMPI-2 in full was used to assess symptoms at baseline and 8 weeks. All three groups showed significant changes in MMPI-2 scores for depression and mania subscales. Gabapentin showed the greatest change in depression symptom improvement relative to lamotrogine and carbamazepine, respectively. Although manic symptoms improved overall, there were no differences between groups in the degree of manic symptom improvement.
Keywords: dysphoric mania, manic-depression, depression, anticonvulsant, mood stabilizer
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference
- Moderate alcohol consumption and cognitive risk




